To investigate the prevalence of APOL1gene in patient on dialysis in the the Netherlands and correlate them to clinical parameters
ID
Source
Brief title
Condition
- Renal disorders (excl nephropathies)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
the primary outcome is the proportion of two high risks alleles of APOL1 gene
in patients on dialysis in the Netherlands
Secondary outcome
The secondary outcome is the proportion of the two high risk alleles of APOL1
gene in patients on dialysis from Western Africa, Suriname, the Netherlands
Antilles and Moroccan and compare this to dialysis patients from Caucasian
background. In addition, the prevalence of kidney disease related monogenic or
polygenic mutations in the dialysis population of Amsterdam and Utrecht.
Background summary
Patients with African ancestors have increased risk of having progressive
kidney disease. One of the possible explanations is the APOL1 (apolipoprotein
1) gene. There have been two high risk alleles (G1 and G2) identified which are
associated with increased risk of non-diabetic kidney disease in African
Americans in the United states of America. Carriers from these risk alleles
have a 4 to 20-fold chance on end stage renal disease (ESRD). The risk of
carriers on ESRD after kidney donation remains up to now speculative. In the
United states of America APOL1 variants are relatively common in African
Americans, but absent in patient from European descent. The prevalence of the
risk alleles among the Caucasian European population is reported to be less
than 1 %. However, in certain urban areas of the Netherlands, such as
Amsterdam, a relatively large proportion of the chronic dialysis population has
a non-Western background. The prevalence of the polymorphisms of the APOL1 gene
in this population is unknown.
Renal transplantation remains the optimal treatment for most patients with
renal failure. It increases patient survival, patient quality of live and
reduces costs. In the Netherlands, renal transplantation with a donor organ
from a live donor is common. More than 50% of all transplantations are
performed with live donor organ, resulting in excellent outcomes.
However, no excess harm should be done to the donor. Removal of the donor
kidney and also late outcomes after transplantation should be as safe as
possible. To this end candidate donors are meticulously screened and evaluated
to make an accurate risk assessment. Up to now family members of non-Western
background are approached by the donor team in a similar way as the Caucasian
families when discussing the subject of organ transplantation and living
donation.
Study objective
To investigate the prevalence of APOL1gene in patient on dialysis in the the
Netherlands and correlate them to clinical parameters
Study design
A cross-sectional study
Study burden and risks
-
meibergdreef 9
Amsterdam 1105AZ
NL
meibergdreef 9
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
all adults on dialysis with given informed consent
Exclusion criteria
all patients who dit not give informed consent
Design
Recruitment
Kamer G4-214
Postbus 22660
1100 DD Amsterdam
020 566 7389
mecamc@amsterdamumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL69157.018.19 |
| Other | NL8530 |